The initial results of the IMbrave050 trial raised hopes that an effective adjuvant regimen for hepatocellular carcinoma (HCC) might finally have arrived.  Patients with HCC treated […]

BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer significantly improved survival, reducing the risk for death by 25%, according […]

BARCELONA, Spain — Breastfeeding is possible even after breast cancer, according to findings from two international studies led by Italian researchers, presented at the European Society […]

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer, according to results of […]

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a […]

BARCELONA, Spain — Hypofractionated radiotherapy is noninferior to conventional fractionation for the locoregional treatment of early breast cancer, suggested new results of a phase 3 trial. […]

BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and bone metastases significantly […]

Several new clinical trials in breast cancer have opened in recent months. Perhaps one of your patients could benefit from taking part? Human epidermal growth factor […]

At a conference on hematologic oncology, two sickle cell experts faced off in a debate about whether gene therapy or alternative stem-cell transplant is the best […]